Article Text

PDF

Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens
  1. P Suwannalai1,
  2. H U Scherer1,
  3. D van der Woude1,
  4. A Ioan-Facsinay1,
  5. C M Jol-van der Zijde2,
  6. M J van Tol2,
  7. T W J Huizinga1,
  8. R E M Toes1,
  9. L A Trouw1
  1. 1Department of Rheumatology, LUMC, Leiden, The Netherlands
  2. 2Department of Pediatrics, LUMC, Leiden, The Netherlands

Statistics from Altmetric.com

Anti-citrullinated protein antibodies (ACPA) are specific for rheumatoid arthritis (RA), their presence is predictive for development to RA and have been implicated in disease-pathogenesis in animal studies. Despite the important implications for diagnoses and etiology, the natural development and biology of the ACPA response is poorly studied. Here the authors determined the avidity and avidity maturation of the ACPA response and compared this to the avidity of antibodies against recall-antigens.

Our data show that the avidity of ACPA against several citrullinated antigens is considerably lower as compared to the avidity of antibodies against recall antigens such as tetanus toxoid or diphtheria toxoid. Intriguingly, despite high titers and extensive isotype switching, no avidity maturation in the ACPA response was observed during longitudinal follow-up.

Our data indicate that the natural evolution of ACPA differs from the development of antibodies against prototype T cell dependent recall antigens. Moreover, these data point to an independency of avidity maturation and isotype-switching where full-isotype switching is taking place in the face of restricted and/or hampered avidity maturation.

As avidity maturation of ACPA differs from avidity maturation of antibodies to recall antigens, our data are of relevance to the design of anti-B cell therapeutics. Intervention in the signalling of BAFF via the different BAFF-receptors may have different results in ACPA producing B cells as compared to ‘conventional’ B cells.

View Abstract

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.